FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered a prolonged release composition for regional depot fat reduction containing a therapeutically effective amount of at least one glucocorticosteroid in the form of a crystalline microparticle suspension, and a therapeutically effective amount of at least one selective beta-2-adrenergic receptor agonist and a respective combined preparation of the same purpose.
EFFECT: glucocorticosteroid reduced beta-adrenergic receptor desensitisation to provide a synergetic action with the beta-2-adrenergic receptor agonist (eg, with formoterol) to enable fat amount reduction.
18 cl, 11 dwg, 5 tbl, 7 ex
